NCT06461936View on ClinicalTrials.gov

Intra-Tumoral Vascular Growth Patterns is a Robust Indicator of Adjuvant Therapy Following Liver Resection in HCC

Active, not recruitingOBSERVATIONAL
Enrollment

620

Participants

Timeline

Start Date

January 1, 2019

Primary Completion Date

April 30, 2024

Study Completion Date

April 30, 2025

Conditions
HCCAdjuvant TherapyImmunotherapyRecurrence
Interventions
DRUG

Sintilimab

Patient receives first adjuvant PD-1monoclonal antibody 2-4 weeks postoperatively, 200mg IV over 21 days for 9 cycles.

DRUG

Lenvatinib

Lenvatinib is initiated orally 2-4 weeks postoperatively for about 6 months.

Trial Locations (1)

430000

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China, Wuhan

All Listed Sponsors
lead

Chen Xiaoping

OTHER

NCT06461936 - Intra-Tumoral Vascular Growth Patterns is a Robust Indicator of Adjuvant Therapy Following Liver Resection in HCC | Biotech Hunter | Biotech Hunter